2020-10-19T11:44:37-05:00 2019-12-31 WITHUMSMITHBROWNPC 4600 EAST WEST HWY 900 BETHESDA MD 208143423 990 2019-01-01 042531031 NATIONAL FOUNDATION FOR CANCER RESEARCH % KWOK LEUNG NATI 3016541250 5515 SECURITY LANE Suite 1105 ROCKVILLE MD 20852 SUJUAN BA PRESIDENT & CEO 3016541250 2020-10-15 true RICHARD L RUVELSON P00234075 3012726000 209.190.253.84 22006220202935000044 2020-10-19 P EBD8DFBC700724A96E49BF1A406FB658268A8823 EBD8DFBC700724A96E49BF1A406FB658268A8823 2019 2021-01-29 14:40:06Z SUJUAN BA 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 14756347 false 5582 X WWW.NFCR.ORG X 1973 MA TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. 6 6 31 100 5727 4086 12714798 9878471 0 0 724768 769613 257329 289821 13696895 10937905 3998229 6224339 0 0 2859084 2882141 51649 64945 2291254 8238769 5360949 15147731 14532374 -1450836 -3594469 13294160 10554744 2997583 3025275 10296577 7529469 X SEE SCHEDULE O false false 7975570 6244339 CANCER RESEARCH - SEE SCHEDULE O 3178841 CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O 11154411 true true false false false true false false false true true false false true true true false true false false false false true true true false false true true true false false false false false false true false true false false false false true false false false true 38 0 true 31 true true true true HK false false false true true false false false false false false false false false X 6 6 false false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X KWOK LEUNG 3016541250 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 X SUJUAN BA PRESIDENT/CEO 40.0 2.0 X 341245 0 72032 FRANKLIN C SALISBURY CEO EMERITUS 40.0 0.5 X 199754 0 47598 YI WANG CHIEF STRTGY OFF. - ALLIANCES 40.0 0.5 X 207686 0 33131 KWOK LEUNG CFO/SECRETARY 40.0 5.0 X 184982 0 28699 BRIAN WACHTEL EXECUTIVE DIRECTOR 40.0 0.0 X 125054 0 17070 BRADLEY GILLENWATER SR. DIR. FOR COMMUNICATIONS 40.0 0.0 X 110714 0 21659 JOSEPH F FRANLIN CHAIR 3.0 0.0 X X 0 0 0 WENDI PICKER TREASURER 1.5 0.0 X X 0 0 0 JUDITH P BARNHARD DIRECTOR 1.5 0.0 X 0 0 0 GUS KODERSHA DIRECTOR 1.5 0.0 X 0 0 0 WILLIAM SCANDONE DIRECTOR 1.5 0.0 X 0 0 0 EDWARD S WEST DIRECTOR 1.5 0.0 X 0 0 0 MICHAEL BURKE DIRECTOR (THRU MAY 2019) 1.5 0.0 X 0 0 0 PADMAKUMAR KAIMAL DIRECTOR (THRU NOVEMBER 2019) 1.5 0.0 X 0 0 0 1169435 0 220189 6 false true false REDFIELD DIRECT LLC 11422 MIRACLE HILLS DR 450 OMAHA NE 68154 LABEL PRINTING 534709 CALMARK GROUP LLC 6755 S SAYRE AVE BEDFORD PARK IL 60638 MAILSHOP 400790 CP DIRECT INC 4600 A BOSTON WAY LANHAM MD 20706 PRINTING 311439 MACKAY MITCHELL ENVELOPE CO 2100 ELM ST SE MINNEAPOLIS MN 55414 ENVELOPE PRINTING 221655 KEY ACQUISITION PARTNERS 181 HARRY S TRUMAN PKWY 265 ANNAPLIS MD 21401 LIST BROKER 167043 7 75166 427176 9376129 188645 9878471 0 261635 261635 0 8933 8933 0 0 0 4268965 3760987 507978 507978 507978 30883 427176 57455 -26572 -26572 0 0 0 0 0 0 MAILING LIST RENTALS 541800 307460 5727 301733 307460 10937905 5727 1053707 5973966 5973966 237373 237373 13000 13000 0 620374 441296 175011 4067 0 1806396 1337662 257075 211659 183526 136146 23582 23798 121225 75116 35088 11021 150620 110265 26366 13989 0 62692 34566 28126 50987 50987 0 64945 64945 45806 45806 259552 115288 141566 2698 160473 24757 131847 3869 116279 37593 74432 4254 423251 260252 5089 157910 0 228678 167921 39656 21101 187557 153061 33152 1344 0 91076 91076 0 0 38096 27914 6666 3516 36819 26957 6457 3405 DIRECT MAIL PROGRAMS 3496875 1801653 1695222 LOCK BOX SERVICE 90397 53479 36918 PROCESS FEES-LIST SALES 44853 26098 18755 MAJOR GIFT 9975 511 9464 17583 8972 5292 3319 14532374 11154411 1086709 2291254 X 3804474 2225557 1578917 1000 1000 1167990 1530154 0 0 106247 201229 0 0 0 0 0 0 0 0 583645 337322 387822 288102 137817 99720 7370729 4349076 442 442 0 0 0 0 3926290 4035801 13294160 10554744 1311474 929618 0 577279 135 135 0 0 0 0 0 0 0 0 0 0 1685974 1518243 2997583 3025275 X 7141083 4057468 3155494 3472001 10296577 7529469 13294160 10554744 -3594469 827361 X false true X true false X 13729474 13952247 11921451 12714798 9898471 62216441 0 0 13729474 13952247 11921451 12714798 9898471 62216441 0 62216441 372780 287499 296562 308859 270568 1536268 16841 9182 647 26670 341191 348604 284518 259968 301733 1536014 65315393 0.95255 0.95411 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 3040 true true 10396983 4136982 286710 6904838 7915837 8699102 7119860 -271815 5150164 10396983 8164316 3394266 213282 3072762 8699102 7627682 3687809 22308 3173483 8164316 7771063 3491261 -158768 3475874 7627682 0.54060 0.27680 0.18260 false false 26890 5727 21163 360932 282375 78557 99720 AMOUNT HELD IN TRUST BY OTHERS 2626641 RIGHT OF USE ASSET 1409160 4035801 0 LEASE LIABILITY 1518243 1518243 X 11847707 827361 20000 111541 958902 10888805 45806 3294 49100 10937905 14636526 20000 133711 153711 14482815 45806 3753 49559 14532374 PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS: THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. PART X, LINE 2 - FIN 48 FOOTNOTE: ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA REQUIRE MANAGEMENT TO EVALUATE INCOME TAX POSITIONS TAKEN AND ACCRUE AN INCOME TAX LIABILITY IF THE ORGANIZATION HAS TAKEN AN UNCERTAIN POSITION THAT MORE LIKELY THAN NOT WOULD NOT BE SUSTAINED UPON EXAMINATION BY THE INTERNAL REVENUE SERVICE. MANAGEMENT HAS EVALUATED THE INCOME TAX POSITIONS TAKEN AND CONCLUDED THAT AS OF DECEMBER 31, 2019 THERE ARE NO UNCERTAIN POSITIONS TAKEN OR EXPECTED TO BE TAKEN THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS. THE NFCR AND AFFILIATES ARE SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS IN PROGRESS FOR ANY TAX PERIODS. IN ADDITION, THERE HAVE BEEN NO TAX RELATED INTEREST OR PENALTIES FOR THE PERIOD PRESENTED IN THESE FINANCIAL STATEMENTS. SHOULD SUCH PENALTIES AND INTEREST BE INCURRED, THE FOUNDATION'S POLICY IS TO RECOGNIZE THEM AS GENERAL AND ADMINISTRATIVE EXPENSES ON THE STATEMENT OF ACTIVITIES. PART XI, LINE 2D - OTHER REVENUES INCLUDED ON FINANCIALS, NOT FORM 990: $112,000 RELATED ORGANIZATIONS' REVENUES $( 459) ROSE PROGRAM EXPENSES -------- $111,541 PART XI, LINE 4B - OTHER REVENUES INCLUDED ON FORM 990 BUT NOT FINANCIALS: $3,294 FOREIGN TAXES WITHHOLDING ON INVESTMENT INCOME DEDUCTED FROM REVENUES ON FINANCIAL STATEMENTS PART XII, LINE 2D - OTHER EXPENSES INCLUDED ON FINANCIALS, NOT FORM 990: $133,711 RELATED ORGANIZATIONS' EXPENSES PART XII, LINE 4B -OTHER EXPENSES INCLUDED ON FORM 990 BUT NOT FINANCIALS: $3,294 FOREIGN TAXES W/H ON INVESTMENT INCOME $ 459 ROSE PROGRAM EXPENSESS ------ $3,753 RESEARCH REVIEW Europe (Including Iceland and Greenland) 1 5000 CHECK RESEARCH REVIEW East Asia and the Pacific 1 5000 CHECK false false false false false false X X X X X X true MERKLE INC 7001 COLUMBIA GATEWAY DRIVE COLUMBIA MD 21046 DIRECT MAIL COUNSEL false 8001401 64945 7936456 8001401 64945 7936456 AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WY DAFFODILS 115883 85000 30883 19434 4485 2058 PLAY 4 THE CURE 307837 307837 25408 50 34339 34339 6070 458059 427176 30883 19434 4485 33536 57455 -26572 true THE TRANSLATIONAL GENOMICS RESEARCH INSTIT 445 NORTH FIFTH ST SUITE 600 PHOENIX AZ 85004 753065445 501(c)(3) 101587 RESEARCH CONTRACTS ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(c)(3) 89177 RESEARCH CONTRACTS CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(c)(3) 113563 RESEARCH CONTRACTS DANA-FARBER CANCER INSTITUTE 44 BINNEY ST MAIL STOP L229 BOSTON MA 02115 042263040 501(c)(3) 100000 RESEARCH CONTRACTS MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 02241 041564655 501(c)(3) 263177 RESEARCH CONTRACTS THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA CA 92037 330435954 501(c)(3) 100000 RESEARCH CONTRACTS VIRGINIA COMMONWEALTH UNIVERSITY PO BOX 980568 RICHMOND VA 23298 546001758 501(C)(3) 100000 20000 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66103 481108830 501(c)(3) 48551 RESEARCH CONTRACTS UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 19104 231352685 501(C)(3) 95223 RESEARCH CONTRACTS SCOTTSDALE HEALTHCARE CORP 8125 N HAYDEN RD SCOTTSDALE AZ 85258 942735850 501(C)(3) 85240 CANCER HOTLINE WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 27157 223849199 501(C)(3) 94961 60000 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS GLOBAL COALITION FOR ADAPTIVE RESEARCH INC PO BOX 427 LEXINGTON MA 02420 821199380 501(C)(3) 525000 RESEARCH CONTRACTS SILCSBIO LLC 8 MARKET PLACE 300 BALTIMORE MD 21230 455174923 100000 TRANSLATIONAL YIVIVA INC 447 BROADWAY 2F NEW YORK NY 10013 811602368 100000 TRANSLATIONAL AIM HI ACCELERATOR FUNDING 5515 SECURITY LN 1105 ROCKVILLE MD 20852 824322538 501(C)(3) 3000000 TRANSLATIONAL AKROTOME IMAGING INC 11000 CEDAR AVENUE CLEVELAND OH 44106 125000 TRANSLATIONAL RASIO THEREAPEUTICS INC 8 MARKET PLACE 300 BALTIMORE MD 21202 833010375 400000 TRANSLATIONAL SCITECH DEVELOPMENT LLC 281 KERCHEVAL AVE GROSSE POINTE MI 48236 383524989 250000 TRANSLATIONAL ANGELINK 16192 COASTAL HIGHWAY LEWES DE 19958 150000 TRANSLATIONAL 13 6 CANCER RESEARCH 5 113709 RESEARCH REVIEW 4 65000 CANCER RESEARCH REWARD 7 40000 TRAVEL FOR CANCER RESEARCH EVENT 7 8664 PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. X X X X X false false false false false false false false false FRANKLIN C SALISBURY JR CEO EMERITUS 198566 0 0 1188 28980 0 18618 0 247352 0 0 0 SUJUAN BA PRESIDENT/CEO 340471 0 0 774 53000 0 19032 0 413277 0 0 0 KWOK LEUNG CFO/SECRETARY 183794 0 0 1188 27598 0 1101 0 213681 0 0 0 YI WANG CHIEF STRTGY OFF. - ALLIANCES 206498 0 0 1188 31064 0 2067 0 240817 0 0 0 FRANKLIN C SALISBURY JR SPOUSE OF SUJUAN BA, PRESIDENT & CEO 199754 WAGE COMPENSATION false X 8 101240 stock market value X CHEMICALS & MATERIALS 3 87405 FMV false true false PART III, LINE 1 - ORGANIZATION'S MISSION: The National Foundation for Cancer Research ("NFCR") is a leading public charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, cures for cancer. NFCR has distinguished itself in the cancer research sector by emphasizing long-term, transformative research often overlooked by other major funding sources. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. Since 1973, NFCR has provided more than $385 million in support of discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. NFCR is committed to fighting cancer by funding high-risk, high-impact, and potentially high-reward discoveries in the labs and transforming them into life-saving treatments for cancer patients. Through global collaboration, NFCR is making unique impact on a new and accelerated path to cures. NFCR envisions a world without cancer! NFCR-funded researchers are making progress every day in their pursuit of cancer cures, and this is only possible with the financial support of millions of donors nationwide. One step at a time, we are getting closer to our ultimate goalcuring cancer, all types of cancer. For more information, please visit www.NFCR.org. THERAPIES THAT HOLD THE HOPE FOR CURING CANCER. NFCR-FUNDED RESEARCHERS ARE MAKING PROGRESS EVERY DAY IN THEIR PURSUIT OF CANCER CURES, AND THIS IS ONLY POSSIBLE WITH THE FINANCIAL SUPPORT OF MILLIONS OF DONORS NATIONWIDE. ONE STEP AT A TIME, WE ARE GETTING CLOSER TO OUR ULTIMATE GOAL-CURING CANCER, ALL TYPES OF CANCER. FOR MORE INFORMATION, PLEASE VISIT WWW.NFCR.ORG. PART III, LINE 4A - CANCER RESEARCH PROGRM ACCOMPLISHMENTS: HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS ============================================ With support from our generous donors, NFCR-funded scientists have made numerous remarkable advances in the fight against cancer. Their research encompasses a wide variety of fields, many of which could ultimately lead to a cure for this deadly disease. Molecular Imaging Improves Detection and Strategic Removal of Cancer Cells ===================================================================== James Basilion, Ph.D. is developing a dual-purpose and sensitive imaging probe. It will allow surgeons to "seedetect prostate cancer cells for better surgical removal. With light activation, the probe can then destroy missed cancer cells and those too risky to remove by surgery. The probe reduces surgical side effects by leaving healthy tissue intact and will reduce the chance of deadly metastasis (when cancer spreads to other parts of the body). The powerful probe, which applies to other cancer types, may soon reach clinical trials. Standard Hypertensive Drug Improves Chemotherapy Response in Ovarian, Breast & Pancreatic Cancers ====================================================================== Cancers can develop resistance to chemotherapy - a significant unmet clinical need for patients and their doctors. Rakesh K. Jain, Ph.D. addressed this challenge by focusing on the layers of fat, immune and other cells (stroma) which compress blood vessels surrounding some tumors and hinder the delivery of chemotherapy, resulting in chemo-resistance. His team discovered that a drug commonly used to control hypertension reduces the stroma surrounding pancreatic, breast and ovarian tumors, allowing for proper blood flow to effectively deliver chemotherapy. A clinical trial combining the drug with chemotherapy has shown very promising results against pancreatic cancer the 3rd deadliest type of cancer. With continued research, this combination treatment may give patients with the 'silent killer' - ovarian cancer - hope for an effective treatment to save their lives. Ancient Enzymes for Protein Synthesis May Help Activate the Immune System to Fight Cancer ======================================================================= The importance of our immune system for keeping cancer at bay has been beautifully demonstrated by the recent success of cancer immunotherapy. Paul Schimmel, Ph.D. and Xiang-Lei Yang, Ph.D. are leading experts in the study of the exquisite enzymes that synthesize all proteins present since very early in evolution. In recent years, they discovered that these enzymes also carry other vital, yet unexpected biological roles. Their latest research shows that one enzyme - SerRS - may activate the immune system to combat cancer. Stay tuned as this research is under close investigation as a potential new cancer immunotherapy. Cutting-edge CRISPR Technology: Identify Genes to Suppress the Metastatic Recurrence of Breast Cancer ===================================================================== Cancer cells that migrate from primary tumors and become circulating tumor cells (CTCs) in the blood can metastasize to a vital organ. Daniel Haber, M.D., Ph.D., is using the gene-editing tool, CRISPR, to identify and turn on or off the genes that regulate the ability of CTC's to metastasize from breast tumors. Several candidate genes have been identified. Ultimately, therapies will be developed that suppress the genes and give women greater hope for surviving the metastatic recurrence of breast cancer. Precision Oncology: Customized Treatment Regimens for Patients ============================================================== One of hallmarks of cancer is chromosomal instability (CIN) or alterations in chromosome number or structure. Precision oncology leader, Wei Zhang, Ph.D., suggests CIN can significantly affect how tumors change and respond to therapy and it could be an option for selecting therapy and targeting chemotherapy resistant cancers. While the field of precision medicine is still in its infancy, NFCR knows the vast promise it holds: with the rise of genomics, scientists can untangle the genetic knot of cancer, tailoring customized treatment regimens for each patient. Target Therapy for Brain Cancer in Clinics ========================================== NFCR-funded scientist, Paul B. Fisher, M.Ph., Ph.D., believes in "thinking outside the box" to generate new research discoveries. Thanks to Dr. Fisher's inventive philosophy, he and his team discovered genetically engineered viruses known as Cancer Terminator Viruses (CTV's), designed to carry anti-cancer agents only to cancer cells, leaving healthy cells untouched. When paired with a powerful immune system modulator, it causes primary and metastatic cancer cells to "commit suicide." Dr. Fisher's therapy is scheduled for use in clinical trials for patients with glioblastoma multiforme (GBM), the aggressive brain cancer claiming lives only 15 months after diagnosis. Continued funding will allow patients diagnosed with metastatic prostate, breast, pancreatic and other cancers to experience this groundbreaking cancer treatment. Supporting the Fight Against Childhood Cancer ============================================= Every year over 300,000 children under the age of 18 are diagnosed with cancer and 90,000 children lose their lives. This number is too high - we must do more to save our children and act quickly! NFCR is committed to making a difference for children and families facing this devastating disease by funding leading scientists working on the development of new drugs designed specifically for pediatric patients. GBM AGILE - Adoptive Global Innovative Learning Environment =========================================================== Glioblastoma Multiforme (GBM) is the deadliest brain cancer with a dismal 3-5% survival rate for the 240,000 patients worldwide diagnosed annually. To address this health crisis, NFCR, led by CEO Dr. Sujuan Ba, has played an instrumental role in forming GBM AGILE, the world's first adaptive clinical trial to improve the survival of GBM patients. This global force included over 150 neurosurgeons, neuro-oncologists, pathologists and other leading doctors and scientists. NFCR's strong financial support of GBM AGILE in the millions of dollars enabled trial sites to begin enrolling patients at cancer care centers in four U.S. cities in 2019. More U.S. sites will open by year-end, and sites in Europe, China and Canada are scheduled to open in 2020. GBM AGILE enables multiple drugs and drug combinations to be screened simultaneously, lowering cost, time, and the number of patients required to evaluate potential new therapies. NFCR'S NEW CANCER PATIENT NAVIGATION HOTLINE ============================================ A cancer diagnosis comes with panic, confusion, uncertainty and questions: What tests should be scheduled? What are the best treatment options? How to communicate the diagnosis with friends and family members? NFCR is HERE to HELP. The hotline provides free assistance through the difficult time by linking a person in need or their family member with our certified oncology nurses (Navigators) and our elite medical team. - Understand the diagnosis and treatment options - Obtain additional opinions from experts and suggestions for treatment - Get recommendations for top oncologists to meet specific needs and help in coordinating that referral process - Learn about clinical trials and the newest therapies for advanced cancer or rare tumors for which no standard care or effective therapy is available PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC: NFCR provides the public with free publications containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message mailed to tens of millions of families and reaching tens of thousands of individuals through our social media channels (twitter and facebook) and through our blogs, helps to assure that fewer of today's healthy individuals will get cancer and more of today's cancer patients will become tomorrow's cancer survivors. Our public education materials include early cancer detection guide, a Childhood Cancer Chart, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENSE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMEBER'S REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN IF NECESSARY, WILL BE FILED. PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. PART VI, SECTION C, LINE19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE. PART IX, LINE 26, JOINT COSTS ALLOCATION: NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 40 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY POSTAL MAIL, EMAIL, PHONE, WEBSITE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT ABOUT CANCER AND UPHOLD ITS MISSION, AND AT THE SAME TIME TO PROVIDE FUNDRAISING OPPORTUNITIES. THE COSTS RELATED TO THESE JOINT ACTIVITIES ARE ALLOCATEDTHEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING. DARWIN FOUNDATION 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 371473821 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR true RESEARCH FOR A CURE 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 010744146 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR true false false false false false false false false false false false false false false false false false false false